Safety of percutaneous cryoablation in patients with painful bone and soft tissue tumors

A single center prospective study (SCIRO-1502)

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This single center prospective study is being conducted to evaluate the safety of the cryoablation for patients with pathologically diagnosed painful bone and soft tissue tumors. Enrollment of 10 patients is planned over the 3-year recruitment period. Patients have related local pain after receiving medications or external radiation therapies will be included in this study. Cryoablation will be percutaneously performed under imaging guidance, and a temperature sensor will be used during treatment as necessary. The primary endpoint is prevalence of severe adverse events within 4 weeks after therapy. The secondary endpoint is effectiveness 4 weeks after the procedure.

Original languageEnglish
Pages (from-to)303-306
Number of pages4
JournalActa Medica Okayama
Volume70
Issue number4
Publication statusPublished - 2016

Fingerprint

Cryosurgery
Radiotherapy
Temperature sensors
Tumors
Bone
Prospective Studies
Tissue
Safety
Imaging techniques
Bone and Bones
Patient Safety
Neoplasms
Pain
Temperature
Therapeutics

Keywords

  • Cryoablation
  • Pain
  • Safety
  • Soft tissue and bone tumor

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

@article{8071b10f902d443d862475475c8f9277,
title = "Safety of percutaneous cryoablation in patients with painful bone and soft tissue tumors: A single center prospective study (SCIRO-1502)",
abstract = "This single center prospective study is being conducted to evaluate the safety of the cryoablation for patients with pathologically diagnosed painful bone and soft tissue tumors. Enrollment of 10 patients is planned over the 3-year recruitment period. Patients have related local pain after receiving medications or external radiation therapies will be included in this study. Cryoablation will be percutaneously performed under imaging guidance, and a temperature sensor will be used during treatment as necessary. The primary endpoint is prevalence of severe adverse events within 4 weeks after therapy. The secondary endpoint is effectiveness 4 weeks after the procedure.",
keywords = "Cryoablation, Pain, Safety, Soft tissue and bone tumor",
author = "Toshihiro Iguchi and Jun Sakurai and Takao Hiraki and Hideo Gobara and Hiroyasu Fujiwara and Yusuke Matsui and Yoshihisa Masaoka and Susumu Kanazawa",
year = "2016",
language = "English",
volume = "70",
pages = "303--306",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "4",

}

TY - JOUR

T1 - Safety of percutaneous cryoablation in patients with painful bone and soft tissue tumors

T2 - A single center prospective study (SCIRO-1502)

AU - Iguchi, Toshihiro

AU - Sakurai, Jun

AU - Hiraki, Takao

AU - Gobara, Hideo

AU - Fujiwara, Hiroyasu

AU - Matsui, Yusuke

AU - Masaoka, Yoshihisa

AU - Kanazawa, Susumu

PY - 2016

Y1 - 2016

N2 - This single center prospective study is being conducted to evaluate the safety of the cryoablation for patients with pathologically diagnosed painful bone and soft tissue tumors. Enrollment of 10 patients is planned over the 3-year recruitment period. Patients have related local pain after receiving medications or external radiation therapies will be included in this study. Cryoablation will be percutaneously performed under imaging guidance, and a temperature sensor will be used during treatment as necessary. The primary endpoint is prevalence of severe adverse events within 4 weeks after therapy. The secondary endpoint is effectiveness 4 weeks after the procedure.

AB - This single center prospective study is being conducted to evaluate the safety of the cryoablation for patients with pathologically diagnosed painful bone and soft tissue tumors. Enrollment of 10 patients is planned over the 3-year recruitment period. Patients have related local pain after receiving medications or external radiation therapies will be included in this study. Cryoablation will be percutaneously performed under imaging guidance, and a temperature sensor will be used during treatment as necessary. The primary endpoint is prevalence of severe adverse events within 4 weeks after therapy. The secondary endpoint is effectiveness 4 weeks after the procedure.

KW - Cryoablation

KW - Pain

KW - Safety

KW - Soft tissue and bone tumor

UR - http://www.scopus.com/inward/record.url?scp=84984846904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984846904&partnerID=8YFLogxK

M3 - Article

VL - 70

SP - 303

EP - 306

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 4

ER -